BraveCX will help analyse chest X-ray images of adults to identify pre-specified suspected clinical findings. Credit: Olga Aniven / Shutterstock.com.

Bering has received the US Food and Drug Administration (FDA) 510(k) clearance for BraveCX, its chest X-ray triage solution powered by artificial intelligence (AI).

The company can now offer its AI solution commercially to healthcare institutions and medical professionals in the US.

The radiological computer-assisted triage and notification software is intended for analysing chest X-ray (CXR) images of adults (≥18 years old) to identify pre-specified suspected clinical findings.

BraveCX was developed to triage and prioritise emergencies like pleural effusion and pneumothorax immediately following the examination.

Physicians receive notifications of findings, offering a ‘second opinion’ and speeding up the diagnosis of urgent cases.

See Also:

The AI-powered product was created using more than one million CXRs from various clinical settings and refined with input from over 50,000 CXRs labelled by board-certified radiologists.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BraveCX achieves specificity rates between 95% and 97% and ROC AUCs of 0.96 for pleural effusion and 0.98 for pneumothorax.

Bering CEO and founder Dr Ignat Drozdov said: “After over three years of research and collaboration with clinical teams, it’s so exciting to see BraveCX emerge as a state-of-the-art tool that has actually ‘listened to the end user’.

“FDA clearance means BraveCX prioritises patient safety, whilst still delivering the most advanced risk stratification algorithms where they are needed the most.”

By utilising a flexible deployment model for a cloud-based service—whether deployed directly on-premises or integrated with CXR hardware systems—the company intends to leverage both new and existing partnerships to swiftly launch the device into the market.

Established in 2010, Bering is a medical AI software company that focuses on developing clinical decision-support systems.